Cosentyx (Secukinumab)

Secukinumab is a medicine used to treat psoriasis, some kinds of arthritis, and a painful skin condition called hidradenitis suppurativa. It is usually given as a shot under the skin, and sometimes as an infusion into a vein. It works by blocking a protein that causes swelling and irritation in the body.

Brand names:Cosentyx
Medication

What people taking Cosentyx (Secukinumab) report

Every report comes from a Lived member, sent anonymously.

Have you tried Cosentyx (Secukinumab) for Psoriasis?

NameHow it went

About Cosentyx (Secukinumab)

What It's For

Secukinumab, sold as Cosentyx, is a prescription biologic: a laboratory-made antibody that blocks one specific signal in the immune system. It treats several long-term inflammatory conditions of the skin, joints and spine. In the US it is approved for moderate to severe plaque psoriasis in adults and children 6 and older whose psoriasis is extensive enough to need whole-body treatment or light therapy rather than creams alone. It also treats active psoriatic arthritis (joint inflammation linked to psoriasis) in adults and children 2 and older, and ankylosing spondylitis (inflammatory arthritis of the spine) in adults and children 12 and older. Adults can use it for non-radiographic axial spondyloarthritis, a related spine condition that causes inflammatory back pain and measurable inflammation but has not yet caused damage visible on X-rays. Children 4 and older can use it for enthesitis-related arthritis, a form of childhood arthritis that inflames the places where tendons attach to bone. It also treats hidradenitis suppurativa (HS), a condition that causes painful lumps, abscesses and draining tunnels under the skin in areas such as the armpits and groin. Cosentyx is approved for moderate to severe HS in adults and children 12 and older.

How It Works

Interleukin-17A (IL-17A) is a signaling protein the immune system uses to switch on inflammation. In psoriasis, psoriatic arthritis, the spine conditions above and HS, the body produces it in excess, and it helps drive the thick, scaly skin plaques, joint and back inflammation, or painful skin abscesses these conditions cause. Secukinumab attaches to IL-17A and stops it from reaching its receptor on cells, which reduces the release of other inflammatory signals further down the chain. The effect is targeted rather than a broad shutdown of the immune system. However, IL-17A also helps defend against some germs. In studies, yeast infections, cold sores and staphylococcal skin infections became more common as blood levels of secukinumab rose, which is why infections are the main trade-off.

Dosage & Administration

Most people use Cosentyx as an injection under the skin, given at home with a prefilled pen or syringe after a clinician has shown them or a caregiver how to do it. Treatment often starts with a loading phase of one dose a week for the first five weeks, followed by one dose every four weeks. For some conditions the prescriber may skip the loading phase, and if the response is not enough, the dose may be raised (for HS, the injections can move to every two weeks). Children's doses are based on body weight, and children should not inject themselves; a trained adult caregiver gives the injection. Injections go into the thigh or abdomen, avoiding the 2 inches around the belly button, or into the upper outer arm if someone else gives it. Use a different spot each time, and avoid skin that is tender, bruised, red, hard or affected by psoriasis. The pens and syringes are kept in the refrigerator and should not be frozen or shaken. The Sensoready pen and the 150 mg and 75 mg syringes can be kept at room temperature for up to four days if needed. Adults with psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis or HS can instead receive Cosentyx as an intravenous infusion at a clinic. It takes about 30 minutes, and the dose is based on weight.

Side Effects

The most common side effects are cold symptoms such as a sore throat and runny nose, other upper respiratory infections, and diarrhea. Infections in general are more frequent: in the first 12 weeks of the main psoriasis studies, about 29 percent of people on Cosentyx had an infection, compared with 19 percent on a placebo (a dummy treatment). Most were mild, but serious infections, including some caused by fungi, bacteria and viruses, can occur. Yeast infections of the mouth or skin and cold sores are more likely at higher doses. Call the care team right away for signs of infection, such as fever, sweats or chills, a cough or shortness of breath, warm, red or painful skin or sores, or burning when urinating. Rarely, secukinumab causes a serious allergic reaction. Swelling of the face, lips, tongue or throat, trouble breathing, throat or chest tightness, or feeling faint after a dose needs emergency medical help right away, and no further doses should be given. Two other reactions are worth recognizing. Inflammatory bowel disease (Crohn's disease or ulcerative colitis) can appear for the first time or flare during treatment, so new or worsening stomach pain or diarrhea should be reported. Severe eczema-like rashes can also develop, anywhere from days to months after the first dose. Report an itchy red rash, dry skin that feels like leather, or blisters on the hands or feet that ooze or crust, because treatment may need to pause.

Interactions & Warnings

Before the first dose, people are tested for tuberculosis (TB). Cosentyx is not started during active TB, and someone with an inactive (latent) TB infection usually begins TB treatment first, because suppressing IL-17A can let the infection reactivate. Hepatitis B has also reactivated in some people, so a past hepatitis B infection should be mentioned, and Cosentyx is not recommended during active viral hepatitis. People who have frequent or long-lasting infections, or who have Crohn's disease or ulcerative colitis, need a careful discussion of whether it is the right choice. Vaccines should be brought up to date before starting. Live vaccines, which contain a weakened form of a virus or bacterium, should be avoided during treatment, so tell anyone giving a vaccine that you use Cosentyx. The removable cap on the Sensoready pen and the 150 mg and 75 mg prefilled syringes contains natural rubber latex, which matters for people with a latex allergy. Cosentyx has few direct drug interactions, but because inflammation affects how the liver processes some medicines, starting or stopping it can shift the levels of certain medicines that need precise dosing. Prescribers should know about all other medicines and supplements. In pregnancy, human data are too limited to judge the risk. Antibodies like secukinumab cross the placenta, increasingly in the third trimester, so a baby may be born with the medicine in its system. Anyone pregnant, planning pregnancy or breastfeeding should weigh the options with the prescriber.

What to Expect

Cosentyx is a maintenance treatment taken on a regular schedule to keep inflammation under control, not a short course. Improvement builds over the first few months. In the main psoriasis studies, about three in four adults on the standard dose had their psoriasis severity score fall by at least 75 percent by week 12, and about six in ten had clear or almost clear skin, compared with around one in twenty on placebo. In psoriatic arthritis and ankylosing spondylitis, roughly six in ten people reached at least a 20 percent improvement on standard measures of joint or back pain, stiffness and function by week 16, compared with about two to three in ten on placebo. The benefit in HS is smaller. By week 16, about four in ten adults had their painful lumps and abscesses cut by at least half without new abscesses or draining tunnels, compared with under three in ten on placebo, though some people improved as early as two weeks in. Response varies. If symptoms are not well controlled after the first few months, the prescriber may raise the dose, shorten the interval or switch to a different treatment. Ongoing follow-up checks how well the condition is controlled and watches for infections, including TB, and for new bowel or skin problems.

Questions to Ask Your Doctor

  1. 1.Why is Cosentyx a good fit for my condition compared with other biologics or treatments?
  2. 2.Will I start with weekly loading doses, and would injections or infusions suit me better?
  3. 3.How will we judge whether it is working, and when would we change the dose or switch?
  4. 4.Which vaccines should I get before starting, and what tests will I need, such as for TB or hepatitis B?
  5. 5.How would Cosentyx fit with pregnancy or breastfeeding plans, or with my other medicines?

Last reviewed • Oct 2026

Educational content, not medical advice.